



FORM 13
 (See rule 46)
 CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
 SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

- Name of Inspector from whom received : SARAH LALDINTLUANGI
 ASSISTANT DIRECTOR (FOOD AND DRUGS)
 Sr. CMO OFFICE, SERCHHIP-796181, SERCHHIP
- Serial No. and date of Inspector's memorandum : 020/IPA/2024 Date 13.12.2024
- Number of Sample : Nil
- Date of receipt : 02-JAN-2025
- Names of drugs purporting to be contained in the sample: CIPROFLOXACIN TABLETS IP 250 mg (Ciprodac 250)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg.	Date of Exp.	Mfg. By
LSD/GUW/2024-25/1603	GUW/LS/2024-25/1641	CT23015	08/2023	07/2026	CADILA PHARMACEUTICALS LIMITED, 1389, Dholka-382 225, Dist.: Ahmedabad.

- Condition of seals on : Seals were intact & identical to the
 [the packet or on portion of sample or container] Specimen impression of the seal received from Drugs Inspector

- Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing : From 17-Jan-2025 To 29-Jan-2025

COMPOSITION : Each film-coated tablet contains:
 Ciprofloxacin Hydrochloride IP
 equivalent to Ciprofloxacin 250 mg

Protocol Applied: I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	White, round, bi-convex, film coated tablet, having a dosage line on one side packed in blister pack.	NA
2	Identification	Gives positive test for Ciprofloxacin.	NA
3	Average weight	0.333195 gm.	NA
4	Uniformity of weight	Complies.	NA
5	Dissolution	Complies {Average drugs release (S_1+S_2) found: 83.75%}.	Average of 12 units (S_1+S_2) is $\geq 80\%$ ($\geq Q$) and no unit is $< 65\%$ of claim (Q-15%).

Assay


Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method

1	Ciprofloxacin Hydrochloride equivalent to Ciprofloxacin	251.06 mg/Tablet	250 mg/Tablet	100.424	90 % to 110 %	I.P. 2022
---	---	------------------	---------------	---------	---------------	-----------

In the opinion of the under signed the sample referred to above is of **standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules thereunder for the reasons given below:-

The sample conforms to I.P. with respect to the above tests only.

Date: 03-FEB-2025



GOVERNMENT ANALYST

Dilip Kr. Sarkar
Government Analyst
R.D.T.L., Guwahati-22

----- END OF REPORT -----

